Dr. Gabriela Hobbs offers her top poster recommendations in myeloproliferative neoplasms presented at the SOHO 2026 Annual Meeting, which include data on a mutant calreticulin-specific antibody in myelofibrosis and the effect of rusfertide in polycythemia vera. The presentations also examine prognostic scoring systems, artificial intelligence models, and real-world treatment patterns for essential thrombocythemia.
- MPN-556: Mutant Calreticulin-Specific Monoclonal Antibody INCA033989 Produces Molecular Responses That Correlate With Clinical Responses in Patients With Myelofibrosis
- MPN-985: Effect of Rusfertide on Cytoreductive Therapy Use in Patients With Phlebotomy-Dependent Polycythemia Vera: Post Hoc Analysis From the Randomized Controlled Phase 3 VERIFY Study
- MPN-425: Baseline Predictors of Survival and Spleen Response in Ruxolitinib-Treated Myelofibrosis: Development of the Ruxolitinib Prognostic Scoring System in
a Real-World Cohort - MPN-1022: Artificial Intelligence vs Conventional Prognostic Models for Survival Prediction in Myelofibrosis: A Systematic Review and Meta-Analysis and External Validation Cohort
- MPN-1090: Real-World Patient Characteristics, Treatment Patterns, and Blood Counts of Patients With Essential Thrombocythemia Treated With Ropeginterferon Alfa-2b in the US Community Oncology Setting
Leave feedback about this